Navigation Links
Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Date:4/14/2008

nc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
3. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
4. Micromet Announces Changes in Management Team
5. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
6. VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
7. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
8. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
9. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
(Date:9/1/2015)... RIVER, Mass. , Sept. 1, 2015   ... an additional 120,000 square feet in Olive Branch, ... Olive Branch facility has added the ... warehousing space. "This expansion gives us the ... Karl Neuberger , President of Millstone MS. "Two and a ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2
(Date:9/1/2015)... ... 2015 , ... Stress comes in many different forms and ... can lead to very serious, life-altering events. Fortunately nature offers a range of ... manufacturer MediHerb has coupled therapeutic doses of Rhodiola and Schisandra herbs ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Horizon Blue Cross ... 50 Best Companies for Latinas in the LATINA Style 50 Report that recognizes companies ... , For 2015, Horizon BCBSNJ climbs from number 24 to 21 of ...
(Date:9/1/2015)... Eagan, Minnesota (PRWEB) , ... September 01, 2015 ... ... covered health care delivery options, Blue Cross and Blue Shield of Minnesota (Blue ... starting in 2016. , Based in San Francisco, Doctor On Demand provides ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... now offering the MonaLisa Touch® , an innovative vaginal health laser procedure ... is a new hormone-free treatment for atrophic vaginitis, a condition that causes vaginal ...
(Date:9/1/2015)... MA (PRWEB) , ... September 01, 2015 , ... ... remote real-time monitoring and analysis of pet vital signs and activity, today announced ... is one of the most popular and widely-adopted veterinary hospital Practice Management Software ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2
... Dr. Barry Sears, ... that, “The obesity crisis and related problems, such as increases in diabetes and heart disease, ... with anti-inflammatory diets, such as the Zone Diet." , ... New Haven, CT (Vocus) June 15, 2010 -- “A majority ...
... a key player in a signaling pathway involved in the ... may offer hope for new targeted melanoma therapies. ... report that a signaling molecule, known as IKKβ, is essential ... disease. The results, published June 7 in the Journal ...
... outcomes, many patients newly-diagnosed with early-stage lung cancer do ... factors associated with this decision include misunderstandings of the ... with black patients more likely to not have surgery, ... of JAMA . Lung cancer is ...
... is 1.3 times higher for those with MRSA in ... News) -- Cystic fibrosis patients with methicillin-resistant staphylococcus aureus ... than those without the drug-resistant bacteria, researchers have found. ... issue of the Journal of the American Medical ...
... Florida Advisory Council on Radiation Protection has endorsed Target ... protection plan. , ASTRO,s Board of Directors developed Target ... safety and quality assurance projects, which began as part ... goal of the plan is to improve safety and ...
... A new book by researchers at Oregon State University ... viewpoint on all types of animal and plant fossils ... they functioned and behaved, especially at the moment of death. ... of a mother, mating and reproductive instincts, to the behavior ...
Cached Medicine News:Health News:Clear Channel's “Penn Project” Features Dr. Barry Sears, Zone Diet Creator, About Obesity in America 2Health News:Tumor target suggests personalized treatment for melanoma 2Health News:Tumor target suggests personalized treatment for melanoma 3Health News:Study examines reasons patients with early stage lung cancer do not have surgery 2Health News:Study examines reasons patients with early stage lung cancer do not have surgery 3Health News:Drug-Resistant Staph Threatens Cystic Fibrosis Patients 2Health News:Florida radiation council endorses ASTRO patient protection plan 2Health News:A new view of fossils: The behavior of ancient life forms 2
... HT is designed for extended temperatures. ... ideal for applications such as DNA ... Incubator/Shaker HT is available as a ... three microplates. Iems Incubator/Shaker HT including ...
... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer for any kind of cell ... CyFlow SL analyzes forward and side ... to 3 fluorescence channels. Data acquisition, ... with a PC or laptop employing ...
Medicine Products: